How to Buy Arcutis Biotherapeutics Stock
Arcutis Biotherapeutics Inc
Arcutis Biotherapeutics, Inc. , a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
Arcutis Biotherapeutics stock last closed at $8.75, up 0.11% from the previous day, and has decreased 34.11% in one year. It has underperformed other stocks in the Biotechnology industry by 0.1 percentage points. Arcutis Biotherapeutics stock is currently +397.16% from its 52-week low of $1.76, and -42.47% from its 52-week high of $15.21.
As of Apr 24, 2024, there are 96.81M ARQT shares outstanding. The market cap of ARQT is $847.12M. In the past 24 hours, 1.79M ARQT shares were traded.
How to Buy Arcutis Biotherapeutics Stock
Wondering how to invest in Arcutis Biotherapeutics stock? Here's how.
- Choose where to buy Arcutis Biotherapeutics stock: You need to pick an online brokerage, but don't worry - we've analyzed dozens of online brokerages and apps to help you determine where to buy Arcutis Biotherapeutics stock.
- Open your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've selected.
- Deposit money your investment account: Pick your payment method and add your info.
- Analyze Arcutis Biotherapeutics stock: The Arcutis Biotherapeutics ticker symbol is ARQT. Is Arcutis Biotherapeutics stock a good investment? Should you buy shares of ARQT? How do ARQT's underlying business fundamentals look? Do top analysts think Arcutis Biotherapeutics is a good buy? Why has ARQT's stock price moved recently? (Hint: Our stock research website can help you figure out if ARQT is a good stock to buy).
- Place your ARQT trade: Decide if you will purchase ARQT shares at the current market price or use a limit order to buy ARQT stock at a specific price.
- Watch your investment in ARQT: Create a watchlist to keep track of your investment in Arcutis Biotherapeutics stock.
Step 1: Choose where to buy Arcutis Biotherapeutics stock
You need an online brokerage account to access the NASDAQ market and buy ARQT shares.
Our favorite brokerage: eToro
Based on our analysis, eToro is the best place to buy stocks. Here's why:
- Invest in stocks with zero commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still buy the stock.
- Access to global markets: From Technology to Energy, New York to Tokyo — you can fill your portfolio with stocks from the world's top exchanges.
- Social investing: eToro offers a community with more than 20 million users globally. Talk to, learn from, and copy the unique crypto portfolios of other investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other financial assets: Such as ETFs and cryptos.
Get $10 towards your share purchase by opening an account with eToro today.
Open eToro AccountStep 2: Open your brokerage account
Now that you've picked the right brokerage, you'll need to fill out some personal information so you are able to buy ARQT stock today.
How to Set Up a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Enter your personal data to open a new trading account.
- Submit your data by pressing the "Create Account" button. Get started with eToro today
Step 3: Deposit money your investment account
Now that you've finished signing up on the best stock market app for beginners, your next step is to transfer the money for your investment:
Watch the walkthrough below to see the process of transferring money into your new investment account.
Step 4: Analyze Arcutis Biotherapeutics stock
Once you have figured out the best place to buy Arcutis Biotherapeutics stock, it's critical to analyze their stock before you buy, so you actually wrap your head around the risk as well as the opportunity.
Arcutis Biotherapeutics quick stats
ARQT Zen Score
WallStreetZen was created to help average investors perform better fundamental analysis quickly.
You can see all of the due diligence checks on ARQT's stock page.
How is ARQT stock valued?
You can use many financial metrics, analyses, models, and charts to gauge ARQT's fair value.
Using relative valuations measures:
- ARQT may be overvalued based on its P/B ratio of 9.55x, relative to Biotechnology industry P/B ratio of 5.86x
You can access additional valuation research on ARQT's stock here.
A quick look at ARQT Financials
Positive Health Checks:
- There are more short-term assets than short-term liabilities on the ARQT balance sheet.
- Total ARQT debt is lower than 5 years ago, relative to shareholder equity.
- ARQT has cash burn of 247485000. It has sufficient cash and short-term investments to cover this for at least one year.
- There are more short-term assets than long-term liabilities on the ARQT balance sheet.
Negative Health Checks:
- ARQT has $272.79M in cash and short term investments. This is not sufficient to cover its annual cash burn of $247.49M.
- ARQT profit margin has gone up by 80.1 percentage points in the past year, but the company is still unprofitable.
- ARQT has a relatively high debt to equity ratio of 2.85.
Do analysts think it's a good time to buy ARQT stock
Out of 4 Wall Street analysts who give forecasts on ARQT, the consensus analyst rating on Arcutis Biotherapeutics is a Strong Buy
It's important to note that analyst forecasts are not recommendations, nor are they investment advice.
You can dive deeper into what analysts are forecasting on the Arcutis Biotherapeutics stock forecast page.
Metrics for Advanced ARQT Traders
How is ARQT performing as a company?
Last year, ARQT revenue was $59.61M. Over the past one years, ARQT's revenue has increased by 1,517.09% per year. This was faster than the Biotechnology industry average of 28.91%.
You can research ARQT's earnings and revenue performance here.
What are ARQT insiders up to?
Over the past year, executives and large shareholders at ARQT have bought more shares than they have sold.
Patrick Burnett, Reporting Persons title Senior Vice President Chief Medical Officer of ARQT, was the latest ARQT insider to sell. They sold $53,180.62 worth of ARQT stock on Mar 4, 2024.
Research more about who owns ARQT shares here.
Does ARQT stock generate passive income?
No, Arcutis Biotherapeutics doesn't provide an income stream by paying out dividends.
Get opinions from other traders
One of the primary reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to learn what other investors have to say.
Step 5: Place your ARQT trade
You have two main types of orders:
- Market order: A market order is an order to buy or sell a security at the best available price.
Market orders are usually fine. - Limit order: A limit order lets you buy or sell a security at a specific price (or better).
If you want to ensure you're buying or selling at a given dollar amount limit, place a limit order.
Click the Open button and eToro will place the order.
If you want more help with buying stocks on eToro, click the how to video below:
Step 6: Watch your investment in ARQT
Now that you own some ARQT stock, you'll want to keep up with your investment.
Add ARQT to a watchlist to keep tabs on your ARQT stock.
ARQT Feed
How to Buy Stock in Arcutis Biotherapeutics
To reiterate, here are the 6 steps to buy stock in Arcutis Biotherapeutics:
- Choose where to buy Arcutis Biotherapeutics stock
- Open your brokerage account
- Deposit money your investment account
- Analyze Arcutis Biotherapeutics stock
- Place your ARQT trade
- Watch your investment in ARQT
If you are looking for a online brokerage, eToro is our favorite venue.
Get Started with eToro TodayIf you want to keep track of your new investment in Arcutis Biotherapeutics, click the button below.
Related Stock Buying Guides
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.